Monday 1 July 2024

The Pharma Letter Podcast — Episode 21 — Will radical new EU regs hobble industry?

Pharmaceutical
Simon Wentworth
31 March 2023
podcast-21-big

More on this story...

Pharmaceutical
EC plans would 'sabotage' pharma industry, trade group says
13 February 2023
Biotechnology
European regulator enhances warning on JAK blocker safety
31 March 2023
Biotechnology
New challenges to navigate to reach regulatory approval, report finds
5 April 2023
Pharmaceutical
European regulatory shake-up fails to impress, as expected
26 April 2023


Related Company News

Data on clinical trials become more accessible in Europe
Europe targets more joined-up health technology assessments
Update on COVID-19 vaccines targeting new SARS-CoV-2 virus variants
EMA issues guidance to help stop drug shortages
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Pharmaceutical

Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Lonza welcomes new CEO Wolfgang Wienand
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze